Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics Portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.


Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.


Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Rapid publication

We are committed to rapid publication and making data, methods and results publicly available as soon as possible

Open collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data


Follow Us


From genomes to medicines: an interview with Ian Dunham

Helena Cornu

14 October 2021

Open Targets Platform 21.09 has been released!

Open Targets Outreach

30 September 2021

Off the beaten path: combining genetic and small molecule approaches to validate novel drug targets

Helena Cornu

16 September 2021

David Gray of the Dundee Drug Discovery Unit shares three key pieces of advice from his career, through the story of the PCLX-001 molecule.

Building the eQTL Catalogue: a Q&A with Kaur Alasoo

Helena Cornu

7 September 2021

Kaur Alasoo explains how the eQTL Catalogue came together, and what their future plans are. The eQTL Catalogue is the largest compendium of uniformly processed eQTL summary statistics and fine-mapping results.

Summer School: A Crash Course in Open Targets, Part 3

Clare West

3 August 2021

Clare West navigates the data downloads for the Open Targets Platform and Genetics portal, showing you how to access and query the data using Spark.

Summer School: A Crash Course in Open Targets, Part 2

Clare West

22 July 2021

Clare West guides you through the data available in the Open Targets informatics tools, with particular focus on the Genetics Portal.

The PROTACtable genome: a systematic assessment of drug target tractability

Helena Cornu

21 July 2021

An Open Targets project has created a framework to assess whether human proteins could be targeted using Proteolysis Targeting Chimeras (PROTACs).

Summer School: A Crash Course in Open Targets, Part 1

Clare West

15 July 2021

Clare West guides you through how to access data from the Open Targets Platform and Genetics Portal using the web interface and GraphQL API

Open Targets Genetics: Version 5 is out!

Open Targets Outreach

30 June 2021

Open Targets Platform 21.06 has been released!

Open Targets Outreach

30 June 2021

Building the Open Targets Platform Interface using React

Alfredo Miranda

3 June 2021

The Open Targets Platform's user interface uses React and JavaScript to present the data produced by the ETL and served through the API.

Presenting Open Targets to the World via Play, Elasticsearch, Clickhouse and GraphQL

Cinzia Malangone, Jarrod Baker

27 May 2021

The next-generation Platform involved a switch from REST to a GraphQL API. Here we discuss the technology used, including Elasticsearch and Clickhouse.

Wheat from the chaff: extracting, transforming, and loading data for Open Targets

Jarrod Baker, Cinzia Malangone

20 May 2021

The Open Targets Platform features a new ETL pipeline, written in Scala and Spark. Here we detail the purpose of the pipeline, and the technology it is based on.

Towards a reproducible ETL: an overview of Open Targets' platform inputs

Cinzia Malangone, Jarrod Baker

13 May 2021

A discussion of how Platform Input support ensures reproducible inputs for our Extract-Transform-Load (ETL) pipeline.

Beyond associations: building therapeutic hypotheses with Open Targets

Ian Dunham, David Hulcoop

6 May 2021

Open Targets directors describe the elements of a full therapeutic hypothesis, and how Open Targets is working to enable the systematic assessment of such hypotheses.

The next-generation Open Targets Platform: rebuilt, redesigned, reimagined

Helena Cornu

29 April 2021

The next-gen Platform presents an improved user experience. It has been rebuilt with leading-edge technologies including Scala, Spark, and React, and includes new features and data.

How we improved our experimental data curation during the COVID-19 lockdown

Panos Zalmas

22 April 2021

Thanks to the expertise of our lab-based research colleagues, we made valuable contributions to our target validation projects in neurodegeneration and immunology & immflammation.

Q&A with Babatomiwa Adebiyi, an intern with the Open Targets Platform

Helena Cornu, David Ochoa

16 April 2021

Babatomiwa Adebiyi is a computer science student at MIT. He tell us about his machine learning project to prioritise targets in our main therapeutic areas: cancer, immune diseases, and neurological diseases

Job seeking during the pandemic: a Q&A with Kostas Tsirigos

Kostas Tsirigos

26 March 2021

How do you prepare for a virtual interview? What is the remote onboarding process like? Open Targets project manager Kostas Tsirigos tells us about his experience.

Open Targets hosts Kiran Musunuru: insights into the genetic basis of coronary heart disease

Helena Cornu

16 March 2021

An insight into Kiran Musunuru's career, from identifying mutations in ANGPTL3 that protect against heart disease, to working on a "vaccination" against heart attacks, and more.